BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences Products
News Nov 15, 2017
To date, there are 122 published articles altogether in this collection. This large collection is an earned honor for BOC Sciences after the past fifteen years of endeavors and fully demonstrates that products offered by BOC Sciences have received enough recognition among scholars and researchers, contributing to the advance of scientific explorations.
Published in Scientific Reports, ACS Applied Materials & Interfaces, Cells as well as dozens of other world-renowned professional scientific magazines and journals, many valuable findings are made concerning a wide range of research topics such as chemical synthesis, discovery of new and novel drugs to treat cancers, high blood pressure, heart disease, etc.
For example, celastrol purchased from BOC Sciences (Shirley, NY) was used as supplemental experimental procedures reagents in the research of obesity treatment. The relevant findings was compiled in an article titled Treatment of Obesity with Celastrol, which was published in Cell.
Founded in 2005 as a company specializing in small-molecule inhibitors, BOC Sciences has now expanded to offer a comprehensive range of chemical products and related solutions in the pharmaceutical industry including bioconjugation, biochemistry, biochemical and cellular analysis, compound synthesis and other clinical studies. “This means that customers now can find nearly whatever they want or need from BOC Sciences, which is the goal we are always striving for,” stated the Manager of Public Relations at BOC Sciences.
As always, BOC Sciences will continue to offer premium chemicals and meanwhile assist its customers with a complete suite of CRO services spanning the entire molecule development.
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE